Lentiviral vector‑based therapy in head and neck cancer (Review)
- Authors:
- Deepak Upreti
- Alok Pathak
- Sam K.P. Kung
-
Affiliations: Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, MB R3E 0T5, Canada, Department of Surgery, Faculty of Medicine, University of Manitoba, Winnipeg, MB R3E 0T5, Canada - Published online on: November 1, 2013 https://doi.org/10.3892/ol.2013.1652
- Pages: 3-9
This article is mentioned in:
Abstract
Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI | |
Parkin DM, Pisani P and Ferlay J: Global cancer statistics. CA Cancer J Clin. 49:33–64. 1999. View Article : Google Scholar | |
Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar | |
Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, Bernstein L, Schoenberg JB, Stemhagen A and Fraumeni JF Jr: Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 48:3282–3287. 1988.PubMed/NCBI | |
Franceschi S, Talamini R, Barra S, Barón AE, Negri E, Bidoli E, Serraino D and La Vecchia C: Smoking and drinking in relation to cancers of the oral cavity, pharynx, larynx, and esophagus in northern Italy. Cancer Res. 50:6502–6507. 1990.PubMed/NCBI | |
Zheng TZ, Boyle P, Hu HF, Duan J, Jiang PJ, Ma DQ, Shui LP, Niu SR and MacMahon B: Tobacco smoking, alcohol consumption, and risk of oral cancer: a case-control study in Beijing, People’s Republic of China. Cancer Causes Control. 1:173–179. 1990. | |
Choi S and Myers JN: Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res. 87:14–32. 2008. View Article : Google Scholar : PubMed/NCBI | |
Bensaad K and Vousden KH: p53: new roles in metabolism. Trends Cell Biol. 17:286–291. 2007. View Article : Google Scholar : PubMed/NCBI | |
Lozano G and Zambetti GP: What have animal models taught us about the p53 pathway? J Pathol. 205:206–220. 2005. View Article : Google Scholar : PubMed/NCBI | |
Agarwal A, Rani M, Saha GK, Valarmathi TM, Bahadur S, Mohanti BK and Das SN: Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell carcinoma. Immunol Invest. 32:17–30. 2003. View Article : Google Scholar : PubMed/NCBI | |
Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, et al: The mutational landscape of head and neck squamous cell carcinoma. Science. 333:1157–1160. 2011. View Article : Google Scholar : PubMed/NCBI | |
Grandis JR and Tweardy DJ: Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 53:3579–3584. 1993. | |
Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD and Tweardy DJ: Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 90:824–832. 1998. | |
Grandis JR and Tweardy DJ: TGF-alpha and EGFR in head and neck cancer. J Cell Biochem Suppl. 17F:188–191. 1993. View Article : Google Scholar : PubMed/NCBI | |
Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol. 22:785–794. 2004. View Article : Google Scholar : PubMed/NCBI | |
Citri A and Yarden Y: EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 7:505–516. 2006. View Article : Google Scholar | |
Kalyankrishna S and Grandis JR: Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 24:2666–2672. 2006. View Article : Google Scholar : PubMed/NCBI | |
Ciardiello F and Tortora G: EGFR antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008. View Article : Google Scholar : PubMed/NCBI | |
Saba NF, Shin DM and Khuri FR: Targeting angiogenesis in head and neck cancer. Curr Cancer Drug Targets. 7:643–649. 2007. View Article : Google Scholar : PubMed/NCBI | |
Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT and Harari PM: Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene. 27:3944–3956. 2008. View Article : Google Scholar | |
Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM and Morrison SJ: Efficient tumour formation by single human melanoma cells. Nature. 456:593–598. 2008. View Article : Google Scholar : PubMed/NCBI | |
Civenni G, Walter A, Kobert N, Mihic-Probst D, Zipser M, Belloni B, Seifert B, Moch H, Dummer R, van den Broek M and Sommer L: Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res. 71:3098–3109. 2011. View Article : Google Scholar : PubMed/NCBI | |
Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF and Ailles LE: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA. 104:973–978. 2007. View Article : Google Scholar : PubMed/NCBI | |
Krishnamurthy S, Dong Z, Vodopyanov D, et al: Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. Cancer Res. 70:9969–9978. 2010. View Article : Google Scholar : PubMed/NCBI | |
Whiteside TL: Immunobiology and immunotherapy of head and neck cancer. Curr Oncol Rep. 3:46–55. 2001. View Article : Google Scholar : PubMed/NCBI | |
Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP and Gabrilovich DI: Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res. 6:1755–1766. 2000.PubMed/NCBI | |
Duray A, Demoulin S, Hubert P, Delvenne P and Saussez S: Immune suppression in head and neck cancers: a review. Clin Dev Immunol. 2010:7016572010. View Article : Google Scholar : PubMed/NCBI | |
Saito T, Kuss I, Dworacki G, Gooding W, Johnson JT and Whiteside TL: Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. Clin Cancer Res. 5:1263–1273. 1999.PubMed/NCBI | |
Zamarron BF and Chen W: Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci. 7:651–658. 2011. View Article : Google Scholar : PubMed/NCBI | |
Kuss I, Donnenberg AD, Gooding W and Whiteside TL: Effector CD8+CD45RO−CD27−T cells have signalling defects in patients with squamous cell carcinoma of the head and neck. Br J Cancer. 88:223–230. 2003. | |
Kuss I, Hathaway B, Ferris RL, Gooding W and Whiteside TL: Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res. 10:3755–3762. 2004. View Article : Google Scholar | |
Campoli M, Chang CC and Ferrone S: HLA class I antigen loss, tumor immune escape and immune selection. Vaccine. 20(Suppl 4): A40–A45. 2002. View Article : Google Scholar : PubMed/NCBI | |
Vora AR, Rodgers S, Parker AJ, Start R, Rees RC and Murray AK: An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma. Br J Cancer. 76:836–844. 1997. View Article : Google Scholar : PubMed/NCBI | |
Kulkarni DP, Wadia PP, Pradhan TN, Pathak AK and Chiplunkar SV: Mechanisms involved in the down-regulation of TCR zeta chain in tumor versus peripheral blood of oral cancer patients. Int J Cancer. 124:1605–1613. 2009. View Article : Google Scholar : PubMed/NCBI | |
Valitutti S, Müller S, Salio M and Lanzavecchia A: Degradation of T cell receptor (TCR)-CD3-zeta complexes after antigenic stimulation. J Exp Med. 185:1859–1864. 1997. View Article : Google Scholar : PubMed/NCBI | |
Sparano A, Lathers DM, Achille N, Petruzzelli GJ and Young MR: Modulation of Th1 and Th2 cytokine profiles and their association with advanced head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. 131:573–576. 2004. View Article : Google Scholar : PubMed/NCBI | |
Whiteside TL: Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor. Curr Cancer Drug Targets. 7:633–642. 2007. View Article : Google Scholar : PubMed/NCBI | |
Jebreel A, Mistry D, Loke D, Dunn G, Hough V, Oliver K, Stafford N and Greenman J: Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer. J Laryngol Otol. 121:246–252. 2007. View Article : Google Scholar : PubMed/NCBI | |
Shevach EM: Regulatory/suppressor T cells in health and disease. Arthritis Rheum. 50:2721–2724. 2004. View Article : Google Scholar : PubMed/NCBI | |
Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S and Kaufman HL: Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol. 24:1169–1177. 2006.PubMed/NCBI | |
Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H and Fujii H: Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer. Br J Cancer. 98:148–153. 2008.PubMed/NCBI | |
Strauss L, Bergmann C and Whiteside TL: Functional and phenotypic characteristics of CD4+CD25highFoxp3+ Treg clones obtained from peripheral blood of patients with cancer. Int J Cancer. 121:2473–2483. 2007.PubMed/NCBI | |
André F, Chaput N, Schartz NE, Flament C, Aubert N, Bernard J, Lemonnier F, Raposo G, Escudier B, Hsu DH, et al: Exosomes as potent cell-free peptide-based vaccine. I Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol. 172:2126–2136. 2004.PubMed/NCBI | |
Mende I and Engleman EG: Breaking tolerance to tumors with dendritic cell-based immunotherapy. Ann NY Acad Sci. 1058:96–104. 2005. View Article : Google Scholar : PubMed/NCBI | |
Steinman RM: Dendritic cells: understanding immunogenicity. Eur J Immunol. 37(Suppl 1): S53–S60. 2007. View Article : Google Scholar | |
Todryk S: A sense of tumour for the immune system. Immunology. 107:1–4. 2002. View Article : Google Scholar : PubMed/NCBI | |
Cools N, Ponsaerts P, Van Tendeloo VF and Berneman ZN: Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. J Leukoc Biol. 82:1365–1374. 2007. View Article : Google Scholar : PubMed/NCBI | |
Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP and Gabrilovich DI: Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 166:678–689. 2001. View Article : Google Scholar : PubMed/NCBI | |
Tas MP, Simons PJ, Balm FJ and Drexhage HA: Depressed monocyte polarization and clustering of dendritic cells in patients with head and neck cancer: in vitro restoration of this immunosuppression by thymic hormones. Cancer Immunol Immunother. 36:108–114. 1993. View Article : Google Scholar | |
Gabrilovich DI, Chen HL, Girgis KR, et al: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 2:1096–1103. 1996. View Article : Google Scholar : PubMed/NCBI | |
Allavena P, Piemonti L, Longoni D, Bernasconi S, Stoppacciaro A, Ruco L and Mantovani A: IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol. 28:359–369. 1998. View Article : Google Scholar | |
Péguet-Navarro J, Moulon C, Caux C, Dalbiez-Gauthier C, Banchereau J and Schmitt D: Interleukin-10 inhibits the primary allogeneic T cell response to human epidermal Langerhans cells. Eur J Immunol. 24:884–891. 1994.PubMed/NCBI | |
Steinbrink K, Wölfl M, Jonuleit H, Knop J and Enk AH: Induction of tolerance by IL-10-treated dendritic cells. J Immunol. 159:4772–4780. 1997.PubMed/NCBI | |
Cerwenka A and Lanier LL: Natural killer cells, viruses and cancer. Nat Rev Immunol. 1:41–49. 2001. View Article : Google Scholar : PubMed/NCBI | |
Yokoyama WM, Kim S and French AR: The dynamic life of natural killer cells. Annu Rev Immunol. 22:405–429. 2004. View Article : Google Scholar : PubMed/NCBI | |
Lee SC, Srivastava RM, López-Albaitero A, Ferrone S and Ferris RL: Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res. 50:248–254. 2011. View Article : Google Scholar : PubMed/NCBI | |
González FM, Vargas JA, López-Cortijo C, Castejón R, Gorriz C, Ramírez-Camacho R, Millán I and Durántez A: Prognostic significance of natural killer cell activity in patients with laryngeal carcinoma. Arch Otolaryngol Head Neck Surg. 124:852–856. 1998. | |
Thomas L: On immunosurveillance in human cancer. Yale J Biol Med. 55:329–33. 1982.PubMed/NCBI | |
Schreiber RD, Old LJ and Smyth MJ: Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 331:1565–1570. 2011.PubMed/NCBI | |
Dunn GP, Bruce AT, Ikeda H, Old LJ and Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 3:991–998. 2002. View Article : Google Scholar : PubMed/NCBI | |
Vattemi E and Claudio PP: The feasibility of gene therapy in the treatment of head and neck cancer. Head Neck Oncol. 1:32009. View Article : Google Scholar : PubMed/NCBI | |
Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, et al: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 314:126–129. 2006. View Article : Google Scholar : PubMed/NCBI | |
Abuzeid WM, Li D and O’Malley BW Jr: Gene therapy for head and neck cancer. Adv Otorhinolaryngol. 70:141–151. 2011.PubMed/NCBI | |
De Costa AM and Young MR: Immunotherapy for head and neck cancer: advances and deficiencies. Anticancer Drugs. 22:674–681. 2011.PubMed/NCBI | |
Harrington KJ, Nutting CM and Pandha HS: Gene therapy for head and neck cancer. Cancer Metastasis Rev. 24:147–164. 2005. View Article : Google Scholar : PubMed/NCBI | |
O’Malley BW, Cope KA, Chen SH, Li D, Schwarta MR and Woo SL: Combination gene therapy for oral cancer in a murine model. Cancer Res. 56:1737–1741. 1996.PubMed/NCBI | |
Case SS, Price MA, Jordan CT, Yu XJ, Wang L, Bauer G, Haas DL, Xu D, Stripecke R, Naldini L, et al: Stable transduction of quiescent CD34(+)CD38(−) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc Natl Acad Sci USA. 96:2988–2993. 1999. | |
Chang LJ and Gay EE: The molecular genetics of lentiviral vectors - current and future perspectives. Curr Gene Ther. 1:237–251. 2001. View Article : Google Scholar : PubMed/NCBI | |
Roe T, Reynolds TC, Yu G and Brown PO: Integration of murine leukemia virus DNA depends on mitosis. EMBO J. 12:2099–2108. 1993.PubMed/NCBI | |
Schroers R, Sinha I, Segall H, et al: Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. Mol Ther. 1:171–179. 2000. View Article : Google Scholar : PubMed/NCBI | |
Kung SK, An DS, Bonifacino A, Metzger ME, Ringpis GE, Mao SH, Chen IS and Donahue RE: Induction of transgene-specific immunological tolerance in myeloablated nonhuman primates using lentivirally transduced CD34+ progenitor cells. Mol Ther. 8:981–991. 2003. View Article : Google Scholar | |
Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C, Sergi Sergi L, Benedicenti F, Ambrosi A, Di Serio C, et al: Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol. 24:687–696. 2006. View Article : Google Scholar : PubMed/NCBI | |
Mahmood S, Kanwar N, Tran J, Zhang ML and Kung SK: SHP-1 phosphatase is a critical regulator in preventing natural killer cell self-killing. PLoS One. 7:e442442012. View Article : Google Scholar : PubMed/NCBI | |
Tran J, Mahmood S, Carlyle JR and Kung SK: Altering the specificity of NK:target cell interactions by genetic manipulation of NK receptor expression on primary mouse NK cells. Vaccine. 28:3767–3772. 2010. View Article : Google Scholar : PubMed/NCBI | |
Hoffmann TK: Systemic therapy strategies for head-neck carcinomas: Current status. GMS Curr Top Otorhinolaryngol Head Neck Surg. 11:Doc032012.(In German). | |
Steeg PS: Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer. 3:55–63. 2003. View Article : Google Scholar : PubMed/NCBI | |
Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2:161–174. 2002. View Article : Google Scholar : PubMed/NCBI | |
Folgueras AR, Pendás AM, Sánchez LM and López-Otín C: Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol. 48:411–424. 2004. View Article : Google Scholar : PubMed/NCBI | |
Noel A, Maillard C, Rocks N, Jost M, Chabottaux V, Sounni NE, Maquoi E, Cataldo D and Foidart JM: Membrane associated proteases and their inhibitors in tumour angiogenesis. J Clin Pathol. 57:577–584. 2004. View Article : Google Scholar : PubMed/NCBI | |
Overall CM and López-Otín C: Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2:657–672. 2002. View Article : Google Scholar : PubMed/NCBI | |
Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM and Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 284:67–68. 1980. View Article : Google Scholar : PubMed/NCBI | |
Sun Y, Liu M, Yang B, Li B and Lu J: Role of siRNA silencing of MMP-2 gene on invasion and growth of laryngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol. 265:1385–1391. 2008. View Article : Google Scholar : PubMed/NCBI | |
Xie SM, Fang WY, Liu Z, Wang SX, Li X, Liu TF, Xie WB and Yao KT: Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 6:552008. View Article : Google Scholar | |
Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003. View Article : Google Scholar : PubMed/NCBI | |
Dean M, Hamon Y and Chimini G: The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res. 42:1007–1017. 2001.PubMed/NCBI | |
Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, Kawakami M, Kagotani K, Okumura K, Akiyama S and Kuwano M: A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 56:4124–4129. 1996. | |
Balkwill F: The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol. 14:171–179. 2004. View Article : Google Scholar : PubMed/NCBI | |
Kang H, Watkins G, Douglas-Jones A, Mansel RE and Jiang WG: The elevated level of CXCR4 is correlated with nodal metastasis of human breast cancer. Breast. 14:360–367. 2005. View Article : Google Scholar : PubMed/NCBI | |
Sokolowska-Wojdylo M, Wenzel J, Gaffal E, Lenz J, Speuser P, Erdmann S, Abuzahra F, Bowman E, Roszkiewicz J, Bieber T and Tüting T: Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. Br J Dermatol. 152:258–264. 2005. | |
Hong JS, Pai HK, Hong KO, Kim MA, Kim JH, Lee JI, Hong SP and Hong SD: CXCR-4 knockdown by small interfering RNA inhibits cell proliferation and invasion of oral squamous cell carcinoma cells. J Oral Pathol Med. 38:214–219. 2009. View Article : Google Scholar : PubMed/NCBI | |
Chen YC, Chen YW, Hsu HS, Tseng LM, Huang PI, Lu KH, Chen DT, Tai LK, Yung MC, Chang SC, et al: Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun. 385:307–313. 2009. View Article : Google Scholar : PubMed/NCBI | |
Chen YC, Chang CJ, Hsu HS, Chen YW, Tai LK, Tseng LM, Chiou GY, Chang SC, Kao SY, Chiou SH and Lo WL: Inhibition of tumorigenicity and enhancement of radiochemosensitivity in head and neck squamous cell cancer-derived ALDH1-positive cells by knockdown of Bmi-1. Oral Oncol. 46:158–165. 2010. View Article : Google Scholar : PubMed/NCBI | |
Badoual C, Sandoval F, Pere H, Hans S, Gey A, Merillon N, Van Ryswick C, Quintin-Colonna F, Bruneval P, Brasnu D, et al: Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies. Head Neck. 32:946–958. 2010. | |
Young MR: Protective mechanisms of head and neck squamous cell carcinomas from immune assault. Head Neck. 28:462–470. 2006. View Article : Google Scholar : PubMed/NCBI | |
Hathaway B, Landsittel DP, Gooding W, Whiteside TL, Grandis JR, Siegfried JM, Bigbee WL and Ferris RL: Multiplexed analysis of serum cytokines as biomarkers in squamous cell carcinoma of the head and neck patients. Laryngoscope. 115:522–527. 2005. View Article : Google Scholar | |
Reichert TE, Rabinowich H, Johnson JT and Whiteside TL: Mechanisms responsible for signaling and functional defects. J Immunother. 21:295–306. 1998. View Article : Google Scholar : PubMed/NCBI | |
Planelles V and Benichou S: Vpr and its interactions with cellular proteins. Curr Top Microbiol Immunol. 339:177–200. 2009.PubMed/NCBI | |
Poon B, Jowett JB, Stewart SA, Armstrong RW, Rishton GM and Chen IS: Human immunodeficiency virus type 1 vpr gene induces phenotypic effects similar to those of the DNA alkylating agent, nitrogen mustard. J Virol. 71:3961–3971. 1997. | |
Stewart SA, Poon B, Song JY and Chen IS: Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation. J Virol. 74:3105–3111. 2000. View Article : Google Scholar : PubMed/NCBI | |
Pang S, Kang MK, Kung S, et al: Anticancer effect of a lentiviral vector capable of expressing HIV-1 Vpr. Clin Cancer Res. 7:3567–3573. 2001.PubMed/NCBI | |
Dai B, Yang L, Yang H, Hu B, Baltimore D and Wang P: HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells. Proc Natl Acad Sci USA. 106:20382–20387. 2009. View Article : Google Scholar | |
Morizono K, Xie Y, Ringpis GE, Johnson M, Nassanian H, Lee B, Wu L and Chen IS: Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med. 11:346–352. 2005. View Article : Google Scholar : PubMed/NCBI | |
Morizono K, Xie Y, Helguera G, Daniels TR, Lane TF, Penichet ML and Chen IS: A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide. J Gene Med. 11:655–663. 2009. View Article : Google Scholar : PubMed/NCBI | |
Morizono K, Pariente N, Xie Y and Chen IS: Redirecting lentiviral vectors by insertion of integrin-tageting peptides into envelope proteins. J Gene Med. 11:549–558. 2009. View Article : Google Scholar : PubMed/NCBI | |
Saenz DT, Loewen N, Peretz M, Whitwam T, Barraza R, Howell KG, Holmes JM, Good M and Poeschla EM: Unintegrated lentivirus DNA persistence and accessibility to expression in nondividing cells: analysis with class I integrase mutants. J Virol. 78:2906–2920. 2004. View Article : Google Scholar : PubMed/NCBI | |
Apolonia L, Waddington SN, Fernandes C, Ward NJ, Bouma G, Blundell MP, Thrasher AJ, Collins MK and Philpott NJ: Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol Ther. 15:1947–1954. 2007. View Article : Google Scholar : PubMed/NCBI | |
Negri DR, Michelini Z, Baroncelli S, Spada M, Vendetti S, Buffa V, Bona R, Leone P, Klotman ME and Cara A: Successful immunization with a single injection of non-integrating lentiviral vector. Mol Ther. 15:1716–1723. 2007. View Article : Google Scholar : PubMed/NCBI | |
Rahim AA, Wong AM, Howe SJ, Buckley SM, Acosta-Saltos AD, Elston KE, Ward NJ, Philpott NJ, Cooper JD, Anderson PN, et al: Efficient gene delivery to the adult and fetal CNS using pseudotyped non-integrating lentiviral vectors. Gene Ther. 16:509–520. 2009. View Article : Google Scholar |